PUT - SPRINTER OPEN END - ELI LILLY & CO | Delayed Deutsche Boerse AG 05:36:39 01/07/2024 pm IST | ||
| 6.3 EUR | +1.29% |
|
| Current month | -59.56% | ||
| 1 month | -61.89% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 01/24/01 | 6.3 | +1.29% |
| 28/24/28 | 6.22 | -12.76% |
| 27/24/27 | 7.13 | -5.94% |
| 26/24/26 | 7.58 | +6.46% |
| 25/24/25 | 7.12 | -6.07% |
Delayed Quote Deutsche Boerse AG
Last update July 01, 2024 at 05:36 pm IST
More quotesStatic data
| Product type | Knock-Out sin Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | 
Vontobel
|
| WKN | VD0KJY |
| ISIN | DE000VD0KJY9 |
| Date issued | 19/02/2024 |
| Strike | 978.7 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 18.03 € |
| Emission volume | N/A |
| Settlement | Por diferencias |
| Currency | EUR |
Technical Indicators
| Highest since issue | 23.86 € |
|---|---|
| Lowest since issue | 5.88 € |
| Spread | 0.22 € |
| Spread % | 3.36% |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
905.4
USD
Average target price
868.9
USD
Spread / Average Target
-4.03%
- Stock Market
- Certificates
- Certificat
